Dogwood Therapeutics Inc (DWTX)

In January 2026, the company announced financing of up to $26.8 million to advance Halneuron® through Phase 2b development, including upfront gross proceeds of $12.5 million. In December 2025, Dogwood Therapeutics announced positive interim Phase 2b clinical trial results for Halneuron® in chemotherapy-induced neuropathic pain, but the stock plunged by 24.7% due to investor concerns about the timeline for final results and the company's cash runway. The company also filed new synthetic Halneuron® intellectual property protection, projected to extend exclusivity up to 2045. In November 2025, Dogwood announced the enrollment of the first 100 patients in its ongoing Halneuron® Phase 2b trial and reported its Third Quarter 2025 financial results, showing a net loss of $15.7 million and cash of $10.1 million. In October 2025, Dogwood Therapeutics scheduled its Third Quarter 2025 financial results for November 6, 2025, and participated in industry summits. In September 2025, Dogwood Therapeutics secured an exclusive worldwide, royalty-free license to develop and commercialize SP16 for cancer-related pain, leading to a significant pre-market surge of 50% in the stock. In August 2025, the company reported its Second Quarter 2025 financial results. In July 2025, Dogwood Therapeutics approved a CFO salary increase and an equity plan amendment. Overall, the stock price has underperformed the S&P500 Index by -46.12% over the past six months.

There is no specific information available regarding demand seasonality for Dogwood Therapeutics, Inc.'s products and services, and demand for its potential future products is unlikely to be subject to significant seasonal fluctuations.

Dogwood Therapeutics, Inc. (DWTX) is a development-stage biotechnology company focused on creating novel medicines for pain and fatigue-related disorders, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical & Biotech industries. Formerly known as Virios Therapeutics, Inc., the company officially changed its name to Dogwood Therapeutics, Inc. in October 2024. The company's primary product candidates include IMC-1, a fixed-dose combination of famciclovir and celecoxib, which has completed Phase 2b clinical trials for the treatment of fibromyalgia and is poised to advance into Phase 3 development. IMC-2, a combination of valacyclovir and celecoxib, is currently in Phase 2 clinical trials for managing fatigue, sleep disturbances, attention issues, pain, autonomic function, and anxiety associated with long-COVID and post-acute sequelae of COVID-19 infection and has demonstrated success in reducing fatigue associated with Long-COVID in clinical trials. Halneuron®, a highly selective sodium channel blocker in Phase 2b clinical trials for the treatment of chemotherapy-induced neuropathic pain (CINP) and cancer pain, is also in pre-clinical trials for burn and ocular pain and has been granted fast track designation from the FDA for CINP. SP16 IV, a low-density lipoprotein receptor related protein-1 (LRP1) agonist, has the potential to treat neuropathy and prevent or repair nerve damage following chemotherapy, for which Dogwood Therapeutics secured an exclusive, royalty-free license in September 2025.

Dogwood Therapeutics, Inc. is headquartered in Alpharetta, Georgia, United States.

Dogwood Therapeutics' brand reputation is reflected through analyst ratings and investor sentiment following company news. MarketBeat indicates a "Hold" consensus rating, while Public.com shows a "Strong Buy" consensus rating. The company's reputation has been affected by clinical trial progress and financial standing, with positive interim Phase 2b results for Halneuron® being offset by investor concerns about the timeline for final results and the company's cash runway. The securing of a license for SP16 for cancer-related pain led to a pre-market stock surge, indicating a positive reception for strategic portfolio enhancements.

Dogwood Therapeutics, Inc. has 19 institutional owners and shareholders, holding a total of 38,897 shares, with major institutional owners including Vanguard Group Inc and Geode Capital Management, Llc. Sealbond Ltd is the largest individual shareholder, owning 24.66 million shares, representing 1,075.59% of the company, while other notable insider owners include William Pridgen, Richard Alan Burch, and Gregory Scott Duncan.